首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis
【24h】

The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis

机译:多激酶抑制剂帕唑帕尼靶向肝星状细胞激活和凋亡,减轻肝纤维化进程

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Tyrosine kinase inhibitors have been emerged recently as an effective therapy against liver fibrosis. The current study was designed to test a potential anti-fibrotic effect of the multi-targeted receptor tyrosine kinase inhibitor pazopanib. Carbon tetrachloride (CCl4; 1 mL/kg) was injected intraperitoneally (i.p.) twice/week for 8 weeks. Pazopanib (10 and 30 mg/kg, i.p.) was administered three times/week at the beginning of week 5. Levels of liver function biomarkers (alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, and total bilirubin), malondialdehyde, transforming growth factor-beta 1 (TGF-beta 1), caspase-3, factor-related apoptosis (FAS), vascular endothelial growth factor (VEGF) receptor-1, and pigment endothelial derived factor (PEDF) were measured. The tissue level of the inflammatory cytokines IL-6 and tumor necrosis factor-alpha (TNF-alpha) were assigned. Fibrotic area was measured by morphometry and expression of alpha-smooth muscle actin (alpha-SMA), caspase-3, platelet-derived growth factor (PDGF) receptor-beta, and matrix metalloproteinase-2 (MMP-2) was scored immunohistochemically. Hepatic expression of collagen-1-alpha-1 (Col1A1) and tissue inhibitor metalloproteinase-1 (TIMP-1) mRNA were assigned by RT-qPCR. Injection of CCl4 resulted in marked collagen deposition, necroinflammation, and fibrosis (2.67 %). Pazopanib in a dose of 30 mg/kg improved liver function, reduced fibrosis (1.48 %), and decreased significantly (P < 0.01) liver expression of malondialdehyde, TGF-beta 1, IL-6, TNF-alpha, Col1A1, TIMP-1, alpha-SMA, MMP-2, PDGF receptor-beta, and VEGF receptor-1. Additionally, the apoptotic markers (caspase-3, FAS) and the anti-angiogenic factor PEDF were upregulated significantly (P < 0.05). Pazopanib at a certain dose level can halt liver fibrosis progression through modulating inflammatory cytokines, suppressing stellate cell activity, inducing apoptosis, and potentially regulating angiogenesis.
机译:酪氨酸激酶抑制剂最近已经出现作为一种抗肝纤维化的有效疗法。当前的研究旨在测试多靶点受体酪氨酸激酶抑制剂帕唑帕尼的潜在抗纤维化作用。每周两次腹膜内(i.p.)注射四氯化碳(CCl4; 1 mL / kg),持续8周。在第5周开始时,每周三次给药Pazopanib(10和30 mg / kg,腹膜内)。肝功能生物标志物(丙氨酸氨基转移酶(ALT),天冬氨酸氨基转移酶(AST),白蛋白和总胆红素),丙二醛的水平,转化生长因子-β1(TGF-β1),caspase-3,因子相关凋亡(FAS),血管内皮生长因子(VEGF)受体1和色素内皮衍生因子(PEDF)进行了测量。炎性细胞因子IL-6和肿瘤坏死因子-α(TNF-α)的组织水平被指定。通过形态计量学测量纤维化区域,并通过免疫组织化学对α-平滑肌肌动蛋白(α-SMA),caspase-3,血小板衍生的生长因子(PDGF)受体-beta和基质金属蛋白酶-2(MMP-2)的表达进行评分。通过RT-qPCR确定胶原蛋白-1-alpha-1(Col1A1)和组织抑制剂金属蛋白酶-1(TIMP-1)mRNA的肝表达。注射CCl4导致明显的胶原蛋白沉积,坏死性炎症和纤维化(2.67%)。帕唑帕尼30 mg / kg剂量可改善肝功能,减少纤维化(1.48%),并显着降低(P <0.01)丙二醛,TGF-β1,IL-6,TNF-alpha,Col1A1,TIMP- 1,α-SMA,MMP-2,PDGF受体β和VEGF受体-1。此外,凋亡标志物(caspase-3,FAS)和抗血管生成因子PEDF显着上调(P <0.05)。一定剂量的帕唑帕尼可以通过调节炎性细胞因子,抑制星状细胞活性,诱导细胞凋亡以及潜在地调节血管生成来阻止肝纤维化进程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号